The Global Biopharma Index

Our Global Biopharma Index is a deep-dive analysis of how the biopharma industry is performing across six key pillars: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, government policy and regulation, and sustainability.

We surveyed 1250 biopharma and healthcare executives to understand the progress, challenges, and opportunities currently confronting the industry both globally and at a regional/country level. The index provides clear recommendations for how we could collectively futureproof the industry for the benefit of human health.

Track the trend.

Here’s how the biopharma industry is performing year over year across six pillars according to our index.

Learn from the leaders.

A quarter of the sample has higher confidence in their country’s biopharma ecosystem across the six pillars. Read the report to see what those leaders have in common.

Supply chain resilience

Confidence in supply chain security is rising – but so are the risks.

Talent pool

Skill shortages remain a challenge in building a capable workforce, as government support slips away.

R&D ecosystem

Digitalization is redefining how R&D happens.

Manufacturing agility

Capacity is expanding, but agility remains a challenge.

Government policy and regulation

Uncertainty and inconsistency are holding the industry back.

Sustainability (new in 2025)

While pressure’s growing for biopharma to prioritize sustainability, progress is slow.

Insights from industry leaders

View more resources

Read the full 2023 report

Read the full 2021 report

Explore how Cytiva can help

Supply chain resilience

We asked industry leaders across the globe for their thoughts on the index topics – here’s what they told us.